These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34032384)

  • 1. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy.
    Chimenti C; Alfarano M; Maestrini V; Galea N; De Vincentis G; Verardo R; Fedele F; Frustaci A
    ESC Heart Fail; 2021 Aug; 8(4):3387-3391. PubMed ID: 34032384
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
    ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
    Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
    J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative bone scintigraphy in wild-type transthyretin cardiac amyloidosis.
    Martini N; Rizzo S; Sarais C; Cipriani A
    BMC Cardiovasc Disord; 2020 Oct; 20(1):466. PubMed ID: 33121442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidental Cardiac Uptake in Bone Scintigraphy Establishing a Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Case Report].
    Chono T; Harada K; Asanuma O
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2023 Dec; 79(12):1370-1374. PubMed ID: 37766520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis.
    Musumeci MB; Cappelli F; Russo D; Tini G; Canepa M; Milandri A; Bonfiglioli R; Di Bella G; My F; Luigetti M; Grandis M; Autore C; Perlini S; Perfetto F; Rapezzi C
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1314-1321. PubMed ID: 31864976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy.
    Iwaya T; Okada A; Tateishi E; Ohta Y; Morita Y; Ohta-Ogo K; Izumi C
    ESC Heart Fail; 2023 Apr; 10(2):1412-1417. PubMed ID: 36335980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis.
    Ungericht M; Groaz V; Messner M; Schuetz T; Brunelli L; Zaruba MM; Lener D; Stocker E; Bauer A; Kroiss AS; Mayr A; Röcken C; Poelzl G
    Amyloid; 2024 Mar; 31(1):22-31. PubMed ID: 37530216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Transthyretin Cardiac Amyloidosis Among Patients Previously Diagnosed With Hypertrophic Cardiomyopathy.
    Rowin EJ; Ruberg FL; Das G; Higgins D; Lipe WC; Bokhari N; Dehn M; Maron BJ; Maron MS
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014938. PubMed ID: 36448453
    [No Abstract]   [Full Text] [Related]  

  • 10. Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.
    Tini G; Sessarego E; Benenati S; Vianello PF; Musumeci B; Autore C; Canepa M
    Eur J Clin Invest; 2021 Dec; 51(12):e13665. PubMed ID: 34390490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Commonly Examined Parameters Is a Useful Predictor of Positive
    Marume K; Takashio S; Nishi M; Hirakawa K; Yamamoto M; Hanatani S; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Sakamoto K; Yamamoto E; Kaikita K; Izumiya Y; Yamashita Y; Ando Y; Tsujita K
    Circ J; 2019 Jul; 83(8):1698-1708. PubMed ID: 31189791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A challenging road to diagnosing transthyretin cardiac amyloidosis and using technetium-99m pyrophosphate bone scintigraphy in nuclear cardiology - A case report.
    Kavita A; Abdul Onny MA; Suppiah S; Abdul Aziz AF; Hashim H; Raja Shariff RE; Ng CS
    Med J Malaysia; 2021 Sep; 76(5):762-767. PubMed ID: 34508392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid heart disease mimicking hypertrophic cardiomyopathy.
    Mörner S; Hellman U; Suhr OB; Kazzam E; Waldenström A
    J Intern Med; 2005 Sep; 258(3):225-30. PubMed ID: 16115295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
    Gillmore JD; Maurer MS; Falk RH; Merlini G; Damy T; Dispenzieri A; Wechalekar AD; Berk JL; Quarta CC; Grogan M; Lachmann HJ; Bokhari S; Castano A; Dorbala S; Johnson GB; Glaudemans AW; Rezk T; Fontana M; Palladini G; Milani P; Guidalotti PL; Flatman K; Lane T; Vonberg FW; Whelan CJ; Moon JC; Ruberg FL; Miller EJ; Hutt DF; Hazenberg BP; Rapezzi C; Hawkins PN
    Circulation; 2016 Jun; 133(24):2404-12. PubMed ID: 27143678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.
    Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP
    Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.
    Treglia G; Glaudemans AWJM; Bertagna F; Hazenberg BPC; Erba PA; Giubbini R; Ceriani L; Prior JO; Giovanella L; Slart RHJA
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1945-1955. PubMed ID: 29687207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone scintigraphy imaging and transthyretin-related (ATTR) cardiac amyloidosis: New tricks from an old tool?
    Duran JM; Borges-Neto S
    J Nucl Cardiol; 2023 Feb; 30(1):368-370. PubMed ID: 35869405
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.